NORDIC BIOTECH PRIVATE INVESTORS ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  1.9% 1.9% 2.5% 3.7% 2.0%  
Credit score (0-100)  71 69 61 51 67  
Credit rating  A A BBB BBB A  
Credit limit (kDKK)  0.8 0.6 0.0 0.0 0.2  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  -29.3 -15.9 -15.3 -20.0 49.5  
EBITDA  -29.3 -15.9 -15.3 -20.0 49.5  
EBIT  -29.3 -15.9 -15.3 -20.0 49.5  
Pre-tax profit (PTP)  261.6 -55.0 -167.6 -1,036.9 23.2  
Net earnings  261.6 -55.0 -167.6 -1,036.9 -7.7  
Pre-tax profit without non-rec. items  262 -55.0 -168 -1,037 23.2  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  2,734 2,679 2,511 1,474 1,467  
Interest-bearing liabilities  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  2,751 2,690 2,523 1,490 1,486  

Net Debt  -786 -756 -734 -713 -712  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  -29.3 -15.9 -15.3 -20.0 49.5  
Gross profit growth  -20.0% 45.5% 4.3% -31.1% 0.0%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  2,751 2,690 2,523 1,490 1,486  
Balance sheet change%  10.5% -2.2% -6.2% -40.9% -0.3%  
Added value  -29.3 -15.9 -15.3 -20.0 49.5  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  -2.0 -3.0 -4.0 -5.0 1.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  100.0% 100.0% 100.0% 100.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  10.2% -1.7% -6.2% -51.3% 1.6%  
ROI %  10.2% -1.7% -6.2% -51.7% 1.6%  
ROE %  10.0% -2.0% -6.5% -52.0% -0.5%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  99.4% 99.6% 99.5% 98.9% 98.7%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  2,685.8% 4,743.6% 4,811.0% 3,565.4% -1,439.3%  
Gearing %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 0.0% 0.0%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  46.9 67.2 64.5 44.6 39.9  
Current Ratio  46.9 67.2 64.5 44.6 39.9  
Cash and cash equivalent  785.6 756.0 733.7 713.1 712.0  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  768.8 744.8 722.3 697.1 734.3  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0